ClinicalTrials.gg
RecruitingNCT06104228Xenon PAH BioUpdated Feb 24, 2026

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

A Phase 2 interventional study of 129Xe Hyperpolarized in Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension and Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), sponsored by Bastiaan Driehuys. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Bastiaan Driehuys · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 313 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Planned enrollment
169th of 253
20 · median 40
Started
2024
with 12 others
Phase 2
82 of 313
11 open now
Primary completion
2027-01
later than 21 of 55 live
Registered
281st of 313
by date

Among the 313 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 169th largest by planned enrollment of the 253 interventional ones that give a count, is one of 13 that started in 2024, is one of 82 in phase 2, reaches primary completion later than 21 of the 55 other live ones, and was the 281st registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

38 of the 313 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of additional assessments, such as labs, echocardiography, and six-minute walk distance (6MWD).

Read the detailed description

Subject Enrollment This study will consent and enroll 20 subjects total.

  • For Arm 1, 10 subjects with Idiopathic Pulmonary Arterial Hypertension (IPAH) will be consented and enrolled. For Arm 2, 10 subjects with Connective Tissue Disease Associated Pulmonary Arterial Hypertension (PAH-CTD) will be consented and enrolled.

Study Design This study will be observational. Subjects in both arms of the trial will undergo a 129Xe MRI/MRS at timepoints of baseline, 3 months, 6 months, and 12 months. In addition to the this, data from standard of care assessments, such as labs, echocardiography, and six-minute walk distance (6MWD), will also collected at these timepoints.

Primary Study Endpoints The primary endpoint for this trial will be the change in defect + low percentage of RBC signal on hyperpolarized 129Xe MRI from baseline to 12 months

Secondary Study Endpoints

There will be several secondary endpoints for this trial:

  • Change in regional and global RBC Oscillation Amplitudes on hyperpolarized 129Xe MR spectroscopy from baseline to 12 months
  • Change in 6MWD from baseline to 12 months
  • Change in NTproBNP from baseline to 12 months
  • Change in WHO FC from baseline to 12 months

Primary Safety Endpoints

There will be several primary safety endpoints for this trial:

  • Frequency of Adverse Events (AE) and/or Serious Adverse Events (SAE)
  • Withdrawals due to adverse event or death
  • Incidence of Adverse Events of Significant Interest (AESI):
  • Electrocardiogram and any findings
  • Physical examination and vital signs
03

Conditions studied

  • Pulmonary Arterial Hypertension
  • Idiopathic Pulmonary Arterial Hypertension
  • Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder)
  • Connective Tissue Diseases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Arm 1 -IPAH

  • Age: 18-75 years
  • WHO functional class 2 or 3
  • Mean pulmonary artery pressures > 20 mmHg
  • Pulmonary capillary wedge pressure ≤15 mmHg
  • Pulmonary vascular resistance > 2 Wood Units (WU)
  • No other cause identified for PAH

Arm 2 -PAH-CTD

  • Age: 18-75 years
  • WHO functional class (FC) 2 or 3
  • Mean pulmonary artery pressures > 20 mmHg
  • Pulmonary capillary wedge pressure ≤15 mmHg
  • Pulmonary vascular resistance > 2 WU
  • Diagnosis of connective tissue disease

Exclusion criteria

Exclusion Criteria:

  • PH other than Idiopathic PAH or PAH associated with CTD; any conditions that prevent the performance of 129Xe MRI scans will be excluded from the study.
05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Other
    Idiopathic Pulmonary Arterial Hypertension

    Arm 1... patients with IPAH

    Drug: 129Xe Hyperpolarized

  • Other
    Pulmonary Arterial Hypertension Associated with Connective Tissue Disease

    Arm 2... patients with CTD-PAH

    Drug: 129Xe Hyperpolarized

Interventions

  • Drug129Xe Hyperpolarized

    Each xenon dose will be limited to a volume less than 25% of a subject's total lung capacity (TLC), as is the case for all protocols currently carried out under IND 109490

06

What researchers measure

Primary outcomes

  1. Pulmonary Vascular Remodeling

    The primary endpoint for this trial will be the change in defect + low percentage of RBC signal on hyperpolarized 129Xe MRI from baseline to 12 months

    Time frame: 1 year

Secondary outcomes

  1. RBC Oscillation Amplitude

    • Change in regional and global RBC Oscillation Amplitudes on hyperpolarized 129Xe MR spectroscopy from baseline to 12 months

    Time frame: 1 year

  2. 6 Minute Walk Distance

    Change in 6MWD from baseline to month 12

    Time frame: 1 Year

  3. NTproBNP

    Change in NTproBNP from baseline to month 12

    Time frame: 1 year

  4. World Health Organization (WHO) Functional Class (FC)

    Change in WHO FC from baseline to month 12

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jan 2027, 28 months after the start.

Of 52 phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Oct 27, 2023
StartActual
Aug 12, 2024
Primary completionEst.
Jan 1, 2027
CompletionEst.
Mar 31, 2027
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06104228
Lead sponsor
Bastiaan Driehuys
Collaborators
American Heart Association
Responsible party
Bastiaan Driehuys (Professor of Radiology, Duke University) — Sponsor-investigator
First posted
Oct 27, 2023
Start date
Aug 12, 2024
Primary completion
Jan 1, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Feb 24, 2026

Study contacts

Claudia Salazar
Contact
claudia.salazar@duke.edu
+1 919 660 2026
Fawaz Alenezi, MD
principal investigator · Duke Univeristy

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion